...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Leukocyte Biology: An Official Publication of the Reticuloendothelial Society >Role of the complement in experimental sepsis.
【24h】

Role of the complement in experimental sepsis.

机译：补体在实验性败血症中的作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

At the Trauma, Shock, Inflammation and Sepsis 2007 conference, the roles of complement activation products and relevant receptors were stressed in the setting of experimental sepsis [cecal ligation and puncture (CLP)] in mice and rats. In addition, some limited evidence was presented related to humans with septic shock (requiring vasopressor support). Collectively, the data suggested that events found in CLP also occur in human sepsis. Experimental sepsis (CLP) in rodents is associated with robust complement consumption and appearance of activation products (C3a, C5a) in plasma. During sepsis, there is up-regulation of C5a receptors (C5aR, C5L2) on blood polymorphonuclear neutrophils (PMNs) and in lungs, liver, kidneys, and heart. CLP also leads to dramatic reductions of C5aRs on blood PMNs, the intensity of which correlates with lethality. Interception in vivo of C5a or C5aR dramatically improves survival after CLP, preserves innate immune functions of blood PMNs, and greatly attenuates the intensity of consumptive coagulopathy and activation of the fibrinolytic system after CLP. In humans with septic shock, there is evidence of complement activation products in plasma along with loss of C5aRs on blood PMNs. These data suggest that in septic humans, interception of C5a or C5aR might be clinically efficacious.
机译：在2007年创伤，休克，炎症和脓毒症会议上，强调了补体激活产物和相关受体在小鼠和大鼠实验性脓毒症中的作用[盲肠结扎和穿刺（CLP）]。此外，一些有限的证据与感染性休克的人有关（需要升压药支持）。总体而言，数据表明在CLP中发现的事件也发生在人类败血症中。啮齿动物的实验性脓毒症（CLP）与稳定的补体消耗和血浆中活化产物（C3a，C5a）的出现有关。败血症期间，血液多形核中性粒细胞（PMN）以及肺，肝，肾和心脏中的C5a受体（C5aR，C5L2）上调。 CLP还导致血液PMN上C5aR的显着减少，其强度与致死率相关。 C5a或C5aR的体内截获可显着提高CLP后的生存率，保留血液PMN的先天免疫功能，并大大减轻CLP后消耗性凝血病的强度和纤溶系统的激活。在患有败血性休克的人类中，有证据显示血浆中补体激活产物以及血液PMN上C5aR的丢失。这些数据表明，在败血性人类中，C5a或C5aR的拦截可能在临床上是有效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号